Marinus Pharmaceuticals (MRNS) & Its Peers Critical Review

Marinus Pharmaceuticals (NASDAQ: MRNS) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Marinus Pharmaceuticals to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.

Risk & Volatility

Marinus Pharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals’ competitors have a beta of 0.86, indicating that their average stock price is 14% less volatile than the S&P 500.

Profitability

This table compares Marinus Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marinus Pharmaceuticals N/A -107.40% -75.54%
Marinus Pharmaceuticals Competitors -3,613.33% -52.24% -8.27%

Earnings and Valuation

This table compares Marinus Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Marinus Pharmaceuticals N/A -$22.16 million -3.69
Marinus Pharmaceuticals Competitors $7.86 billion $2.50 billion 1.01

Marinus Pharmaceuticals’ competitors have higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Marinus Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marinus Pharmaceuticals 0 0 2 0 3.00
Marinus Pharmaceuticals Competitors 942 3778 5989 164 2.49

Marinus Pharmaceuticals presently has a consensus price target of $7.00, suggesting a potential upside of 70.73%. As a group, “Pharmaceuticals” companies have a potential upside of 26.00%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Marinus Pharmaceuticals is more favorable than its competitors.

Institutional and Insider Ownership

28.8% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.4% of Marinus Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Marinus Pharmaceuticals competitors beat Marinus Pharmaceuticals on 7 of the 12 factors compared.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply